Want to see MANE full AI Analyst Report?
MANE Stock Chart & Stats
$102.82
--
Market closed
$102.82
--
Day’s Range― - ―
52-Week Range$32.00 - $131.24
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$4.11B
Enterprise Value$4.32K
Total Cash (Recent Filing)$819.89M
Total Debt (Recent Filing)$428.00K
Price to Earnings (P/E)―
Beta-0.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,780,136
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-10.94
Price to Sales (P/S)0.00
P/FCF Ratio-18.49
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$169.20Price Target Upside64.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Extended Operating RunwayThe follow-on financing materially strengthens liquidity and can fund multiple Phase 3 readouts and launch preparations through 2030. This reduces near-term financing pressure while the company advances its lead program toward potential commercialization.
Positive Clinical Progress In Female Pattern Hair LossPositive female pattern hair loss data and completed enrollment in the registration-directed Study 306 improve development visibility. If confirmed in later readouts, the program could address an important unmet need and broaden the potential product opportunity.
Broad Late-stage Development ProgramA multi-study program spanning male and female pattern hair loss provides several paths to clinical validation and eventual market entry. The proprietary extended-release oral formulation and sizable controlled trials support a potentially differentiated product platform.
Bears Say
No Commercial RevenueWith no current revenue or gross profit, the business has not yet demonstrated commercial demand or a self-sustaining operating model. Its future value depends heavily on successful clinical development, regulatory approval and eventual product adoption.
Accelerating Losses And Cash BurnRapidly increasing losses and cash outflows indicate that clinical development remains expensive and the company cannot fund operations internally. Continued spending across several trials raises the risk that additional capital will eventually be required.
Deeply Negative Equity And Funding DependenceThe sharp deterioration in net worth weakens financial flexibility despite minimal debt. A deeply negative equity position increases dependence on external financing and leaves the company more exposed to dilution or other funding constraints if development costs rise.
MANE FAQ
What was Veradermics, Incorporated’s price range in the past 12 months?
Veradermics, Incorporated lowest stock price was $32.00 and its highest was $131.24 in the past 12 months.
What is Veradermics, Incorporated’s market cap?
Veradermics, Incorporated’s market cap is $4.11B.
When is Veradermics, Incorporated’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Veradermics, Incorporated’s earnings last quarter?
Currently, no data Available
Is Veradermics, Incorporated overvalued?
According to Wall Street analysts Veradermics, Incorporated’s price is currently Undervalued.
Does Veradermics, Incorporated pay dividends?
Veradermics, Incorporated does not currently pay dividends.
What is Veradermics, Incorporated’s EPS estimate?
Veradermics, Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Veradermics, Incorporated have?
Veradermics, Incorporated has 41,780,136 shares outstanding.
What happened to Veradermics, Incorporated’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Veradermics, Incorporated?
Currently, no hedge funds are holding shares in MANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veradermics, Incorporated Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$169.20 (64.56% Upside)
$169.20 (64.56% Upside)
Blogger Sentiment
Bullish
MANE Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 766.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $103.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Veradermics, Incorporated
Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. Veradermics caters to healthcare practitioners and clinicians specializing in dermatologic and aesthetic care for patients of all ages, in addition to the wider medical and scientific community engaged in dermatology. Founded in 2019, the company is based in New Haven, Connecticut.
MANE Stock 12 Month Forecast
Average Price Target
$169.20
▲(64.56% Upside)
Vericel
―
Veracyte
―
Kiniksa Pharmaceuticals
―
Arcutis Biotherapeutics
―
Caris Life Sciences, Inc.
―
Ownership Overview
18.00% Insiders
1.03% Mutual Funds
42.56% Other Institutional Investors
32.35% Public Companies and
Individual Investors